SAN DIEGO--(BUSINESS WIRE)--Dexcom, Inc., (NASDAQ:DXCM), a leader in continuous glucose monitoring (CGM), announced today that the U.S. Food and Drug Administration (FDA) has approved new software for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

This latest software enhancement to DexCom G4 Platinum will make the performance level of blood glucose monitoring comparable to finger stick meters, the traditional standard-of-care for the same.

The FDA has approved updat- ed, more accurate software for the Dexcom G4 Platinum pediatric continuous glucose monitoring (CGM) system. The approval, granted May 22, 2015, reflects soft-ware changes ...

DexCom, Inc. ( DXCM) recently revealed the U.S. Food and Drug Administration (FDA) approval for a new algorithm designed for its G4 PLATINUM Continuous Glucose Monitoring (CGM) system. Following the ...

In May 2026, Dexcom disclosed FDA-enforced, Class II voluntary recalls of its G7 and ONE/ONE+ iOS and watchOS apps worldwide due to a software defect that can delay or replay glucose readings and ...

DexCom, Inc. DXCM is well positioned for growth in the coming quarters, supported by the significant potential of the ...